Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2014—Meridian Life Science now has a sampling kit with HIV-1 p24 reagents for developing sensitive and specific HIV-1 p24 sandwich immunoassays. The kit includes a 0.25-mg vial of capture antibody, MAb to HIV-1 p24; a 0.25-mg vial of detection antibody, MAb to HIV-1 p24; and a 0.25-mg vial of recombinant HIV-1 p24 antigen (strain HxB2) expressed in Pichia pastoris. Meridian Life Science, 901-382-8716
July 2014—To accommodate growing order volumes, BioMérieux has integrated Esker’s cloud-based order processing automation solution within its SAP environment for electronic order management. Esker’s intelligent data capture technology accurately extracts order information while automated workflow routes the orders to the appropriate customer service representative.
July 2014—OpGen launched a molecular-based test that can identify patients at risk for harboring serious disease-causing, antibiotic-resistant microbes, the Acuitas MDRO Gene Test. The test uses DNA amplification and detection technology to detect as many as seven genes from one patient sample—genes associated with deadly bacteria, including carbapenem-resistant enterobacteriaceae containing KPC, NDM-1, and OXA-48 genes—within 24 hours.
July 2014—Audit MicroControls added ready-to-use vitamin D linearity and control kits to its line of calibration verification/linearity and daily quality control products. These liquid, human serum–based products are intended for use with quantitative assays on clinical laboratory analyzers, simulating human patient serum samples. The Linearity LQ Vitamin D (universal) and Linearity LQ Vitamin D Roche both have five levels that demonstrate a linear relationship to each other when assayed for vitamin D, have a shelf life of two years, and an open-vial stability of 14 days when stored at 2°–8°C.
July 2014—Dako and Merck & Co. will collaborate to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer. The companion diagnostic test coming out of this collaboration will be evaluated as part of the clinical development program from Merck’s investigational anti-PD-1 antibody being studied for the treatment of cancer.
July 2014—Health Canada approved Roche’s Cobas 4800 HPV Test for use as a first-line primary screening test for cervical cancer in women 25 and older. Roche also launched the fully automated CINtec Plus test to improve the detection and early intervention of precancerous cervical disease. The Health Canada–approved CINtec Plus cytology test helps identify women with high-grade precancerous cervical lesions who need immediate colposcopy.
July 2014—Vermillion launched Aspira Labs, which will specialize in using a biomarker-based diagnostic algorithm to inform clinical decision-making and advance personalized treatment plans in the management of gynecologic cancers. The lab, based in Austin, Tex., will also serve as an education and resource hub for health care professionals and women facing surgery for ovarian masses that are potentially cancerous and other related gynecologic conditions.
July 2014—Meridian Life Science now has a sampling kit with HIV-1 p24 reagents for developing sensitive and specific HIV-1 p24 sandwich immunoassays. The kit includes a 0.25-mg vial of capture antibody, MAb to HIV-1 p24; a 0.25-mg vial of detection antibody, MAb to HIV-1 p24; and a 0.25-mg vial of recombinant HIV-1 p24 antigen (strain HxB2) expressed in Pichia pastoris
July 2014—Qiagen’s artus C. difficile QS-RGQ MDx Kit received FDA clearance, and its QIAsymphony RGQ MDx system was granted 510(k) regulatory clearance by the FDA. In addition, the artus VanR QS-RGQ MDx Kit for detection of vancomycin-resistant bacteria, available in Europe, is expected to be submitted to the FDA this year. The artus MRSA QS-RGQ MDx Kit for methicillin-resistant Staphylococcus aureus is expected to be launched in Europe this year and submitted to the FDA in the third quarter of 2014. Test kits for diagnosis of group B streptococcus and herpes simplex virus (HSV 1/2) are in the advanced stages of development.
July 2014—DiaSorin received FDA clearance for its Liaison N-Tact PTH Gen II immunoassay, intended for the quantitative determination of intact human parathyroid hormone in human serum and plasma samples. The kit contains 200 tests and has an open-kit shelf life of 8 weeks, meeting the needs of small- and large-volume laboratories. It also has low cross-reactivity to the 7-84 and other inactive fragments, supporting conservative patient management.
